Curis Reports Positive Progress in Blood Cancer Drug Trials, Eyes December Data Readout
On July 27, 2026, Curis Inc. (CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, an oral IRAK4 and FLT3 inhibitor being developed to treat blood cancers. The company also provided revised guidance on the timeline of ongoing trials, including expanded enrollment in the TakeAim CLL study. HC Wainwright analyst Sara Nik highlighted that patient consent numbers have increased faster than expected, with 10 patients enrolled as of July 2026 and a projected year-end target of 5-10 participants. The firm reiterated its Buy rating on Curis' stock but raised the price forecast from $17 to $43. Nik noted that these updates add valuation potential for emavusertib in Chronic Lymphocytic Leukemia (CLL), assuming a 2032 commercial launch and peak sales of up to $500 million. The estimated timelines for other indications, including PCNSL and AML/MDS, have also been pushed back due to enrollment delays or funding dependencies. The December data readout is seen as the next key milestone by analysts, with potential upside from registrational cohort results in PCNSL and possible expansion into additional NHL subtypes. The drug's duration of response in BTK inhibitor-experienced patients has exceeded expectations, offering reassurance for regulatory approval prospects.
Topics: biotech blood_cancer curis emavusertib